ALK and non-small cell lung carcinoma: The efficacy of this combination regimen is supported by KEYNOTE-189 and -021 clinical trial results demonstrating superior overall survival (OS) for patients with advanced or metastatic nonsquamous NSCLC and no EGFR or ALK genomic aberrations who were treated with first-line pembrolizumab plus pemetrexed-platinum as compared with placebo plus pemetrexed-platinum (8–12).